



THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

SEP 23 2002

RECEIVED

In re the Application of
Roland A. Carlsson et al.
Serial No. 09/734,801
Filed: December 12, 2000
For: A METHOD FOR IN VITRO
MOLECULAR EVOLUTION OF
PROTEIN FUNCTION

) Group Art Unit: 5194
)
) Examiner: S. Chunduru
)
) Response to Paper No. 8
)
)
)
)
)
)

DECLARATION OF CARL BORREBAECK

I, Carl A.K. Borrebaeck, hereby declare that:

1. I am a citizen of Sweden and reside at Ättevägen
8B, 245 62 Hjärup, Sweden.

2. I received a M.S. degree in Chemical Engineering
and a Ph.D. degree in Biochemistry 1979 (with a subspecialty in
Molecular Immunology), respectively, from Lund University. I
have been a member of the faculty of Lund University since 1982.
I am currently a Professor and Chairman in the Department of
Immunotechnology at Lund University. The details of my
education and professional history are set forth in my
curriculum vitae, attached hereto as Exhibit A.

3. I have over twenty-five years of experience in the
field of immunology, my particular area of expertise being in
molecular immunology/biology.

4. I am the author or co-author of 178 scientific
articles on the subjects of biochemistry, immunology, and
immunotechnology. A list of these articles is set forth in my

Curriculum vitae, attached hereto. My current areas of research involve the development of methods for generating novel polynucleotides and encoded polypeptides thereof, the generation of agents having utility for antibody based immunotherapy, and the use of protein microarrays in target discovery assays.

5. I am a co-inventor of the subject matter disclosed and claimed in U.S. Patent Application Serial No. 09/734,801, entitled "A METHOD FOR IN VITRO MOLECULAR EVOLUTION OF PROTEIN FUNCTION." (hereinafter "the '801 application").

Statements Regarding Issues Related to Judicially Created Doctrine of Obviousness-Type Double Patenting, Anticipation, and Obviousness

6. I have read and am familiar with the Official Action dated April 16, 2002, in the '801 application. I understand the nature of the rejections made by the Examiner concerning the doctrine of obviousness-type double patenting, anticipation, and obviousness. I have also read the references cited in connection with the rejections set forth in the Official Action of April 16, 2002. In particular, I understand that it is the Examiner's position that the claimed invention is inherent in the teachings and anticipated by the disclosure of U.S. Patent No. 6,159,690 and obvious in view of U.S. Patent No. 5,811,238 (hereinafter referred to the '238 patent) considered in combination with Berger (1994, *Analyt Biochem* 222:1-8).

7. As exemplified in the specification, my co-inventors and I have devised an improved method for the generation of novel polynucleotides and polypeptides encoded thereby, wherein such novel products may be selected for advantageous properties. The improved method involves the use of single stranded, as opposed to double stranded, DNA in gene shuffling methods to provide superior frequencies of functional recombinant end-products.

In order to provide improved methods for gene shuffling, different experimental parameters were varied to investigate the impact of such changes on the functional outcome of the process. As described hereinbelow, experiments were performed to compare the utility of single stranded versus double stranded DNA in the methods of the present invention. Of note, there is a strong tendency for double stranded fragmented genes to form homoduplexes rather than heteroduplexes upon PCR-mediated recombination. Clearly, the formation of homoduplexes would lead to the re-generation of the parent polynucleotides and thus, render the process of limited utility for the production of novel polynucleotide sequences. When engineering novel polynucleotides by shuffling different family member genes, therefore, it is important to achieve an efficient recombination frequency in order to optimize the diversity of the end-product shuffled polynucleotides.

In order to evaluate the effects of altering various experimental parameters on recombination frequency among family member genes, three different scFv antibody fragments (CT17, SMUC, and F8) were used as starting material for DNA shuffling. These scFvs differ only in the six hypervariable loops. For these experiments, double stranded and single stranded polynucleotides encoding each of the three scFv antibodies were isolated. For clarity, the procedures for double stranded and single stranded polynucleotide starting material will be described separately. An equimolar mixture of the three scFv double stranded polynucleotides was used in fragmentation reactions and fragmented double stranded polynucleotides reassembled by PCR to produce full length genes. For single stranded shuffling experiments, plus and minus strand populations for each of the scFv fragments were generated by PCR amplification. The plus strand was amplified using a

biotinylated primer, the incorporation of which facilitated the isolation of the biotinylated plus strand PCR product using streptavidin-magnetic beads. The complementary strand, the minus strand, was also amplified in parallel using an unbiotinylated primer. The minus strand PCR product, therefore, remained in solution after affinity purification of the biotinylated plus strand with streptavidin-magnetic beads. Equimolar mixtures comprising either the plus strands or the minus strands of the three scFv polynucleotides were generated. The plus and minus single stranded polynucleotide population mixtures were digested separately to produce plus and minus single stranded fragments. The resultant fragmented plus and minus single stranded populations were subsequently mixed and reassembled by PCR to produce full length genes. Shuffled full length genes derived from double stranded or single stranded starting material were subcloned and individual clones sequenced. An optimum in recombination frequency was identified, which was dependent on the duration time of fragmentation. See Exhibit B.

These experiments revealed the surprising result that the frequency of clones having at least one recombination event was significantly higher for shuffled single stranded digested polynucleotide populations than for shuffled double stranded digested polynucleotide populations. Sixty percent of the clones derived from shuffling single stranded starting material had a least one recombination, whereas only forty percent of such recombinants was obtained following shuffling of double stranded starting material. Of note, high recombination frequency is the basis for an efficient shuffling technology. See Exhibit B.


The foregoing data clearly show the superior and unexpected results for producing polynucleotide variants

achieved using exonucleolytic digestion of single stranded DNA as the starting material in DNA shuffling methods of the present invention.

8. The experimental data provided in Exhibit B and the methodology provided in the '801 application, set forth clear evidence that the use of single stranded DNA in DNA shuffling protocols provides an unexpected advantage over the use of double-stranded DNA for the generation of novel and improved polynucleotides and polypeptides encoded thereby. This method differs significantly from that disclosed in the '690 patent as no template is employed. Furthermore, one of skill in the art would not have been motivated to alter the method of Stemmer or the method of Berger to arrive at the presently claimed invention as these methods rely on the use of double stranded DNA as starting materials. Additionally, there is no teaching or suggestion of the advantages of using single stranded DNA as a starting material to generate improved polypeptide encoding nucleic acids via gene shuffling as set forth in Exhibit B in either of these references.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful statements may jeopardize the validity of the above-referenced application or any patent issued thereon.

2002-08-05
DATE



Carl A.K. Borrebaeck
CARL A. K. BORREBAECK
Professor
Dept. of Immunotechnology
University of Lund, Sweden

99-11-30

Carl A.K. Borrebaeck - CV**Office Address:**

Department of Immunotechnology
University of Lund, P.O.Box 7031
S-220 07 Lund, Sweden
Phone: +46-46-222 9613
Fax: +46-46-222 4200
Email: carl.borrebaeck@immun.lth.se
<http://www.kc.lth.se/immun/default.html>

Home Address:

Ättevägen 8B
S-245 62 Hjärrup
Sweden
Phone: +46-40-46 22 46

Personal:

Date and Place of Birth: October 21, 1948, Halmstad, Sweden.
Marital Status: Married 1981 to Camilla Brunnby, B.Sc., three children.
Citizenship: Swedish

Languages:


English, German.

Education:

1966-69 Halmstad Highschool of Technology (Tekniskt gymnasium).
1971-74 University of Lund, Lund, Sweden, B.Sc. (Mathematics, Biochemistry, Physics).
1974-76 Lund Institute of Technology (LTH), M. Chem. Eng. (Chemistry/Biochemistry).
1976-79 Lund University/Lund Institute of Technology, D.Sc. (Biochemistry, with special emphasis on Molecular Immunology).

Senior Academic Positions:

1980-1981 Visiting Scientist/Postdoctoral Fellow, Department of Biochemistry, University of California, Davis, USA (with Professor Marilyn E. Etzler).
1981-1984 Senior Research Associate (Forskningsassistent), Department of Pure and Applied Biochemistry, Lund University.
1982-1984 Assistant Professor of Biochemistry (Oavlonad Docent), Department of Pure and Applied Biochemistry.
1984 Deputy Professor of Biochemistry (T.f. Professor), Department of Pure and Applied Biochemistry.
1985 Deputy Associate Professor of Immunotechnology (T.f. Docent), Department of Biotechnology, Lund University.



99-11-30

1985-1989	Associate Professor of Immunotechnology (Docent), Department of Biotechnology.
1989	Deputy Professor of Immunotechnology (T.f. Professor), Department of Biotechnology.
1990- 1994-1998	Professor of Immunotechnology, Department of Immunotechnology. Deputy Chairman of the Wallenberg Laboratory, Lund University.
1998-2000	Chairman of the Wallenberg Laboratory, Lund University
1996-1997	Nominated and selected as OMRF Esther Z. Greenberg Scholar, Oklahoma Medical Research Foundation, Oklahoma City.
1998	September 1998 as Visiting Greenberg Professor, Oklahoma Medical Research Foundation, Oklahoma City.

Board Member of National Research Councils:

1996-2000	The Swedish Research Council for Engineering Sciences (TFR), Executive Board Member
1999-2000	Chairman Biotechnology Section, The Swedish Research Council for Engineering Sciences (TFR) Executive Board
1999	Inter- Research Council Working Party on Functional Genomics
1999	National Committee for Molecular Biology (representative of TFR)

Industrial & Financial experience:

1. Company Boards:

1983-presently	Cofounder and Board Member of BioInvent International AB, Lund, Sweden.
1-1993	Board member Pronova Oncology (Oslo)
1-2000	Board member of Innovation Stipend Selection Committee (Teknikbrostiftelsen)
1998-	Board Member Teknikbrostiftelsen (Technology Transfer Foundation)
1998-	Chairman of the Board, Lund University Technology Group, (Forskarpatent i Syd AB)
1-2000	Board Member Teknopol AB (Lund University Business Consulting)
2000 -	Board Member TeknoSeed AB (Seed Capital Investments)
2001-	Cofounder and Board Member of Alligator Bioscience AB, Lund,

Sweden

2. Operative Industrial Positions

1987-	Senior Vice President - CSO, BioInvent Int. AB.
1-1994	President & CEO, BioInvent Int. AB.

3. Scientific Advisory Boards:

1-1994	Member of the Research Selection Committee of Pronova A/S
2000-2003	Scientific Advisory Board to Academy of Finland for the Finnish Center

of Excellence: VTT Industrial Biotechnology

4. Financial and Capital Market experience:

- 1-1995 Research consultant to major/intermediate pharmaceutical companies in USA and Sweden.
1999- Advisory Board Member to InnovationsKapital AB (Venture Capital)

Selected European Commission Awards

- BIO2-CT92-0269 "In vitro immunization of human B lymphocytes", total grant 15 MSEK
BIO4-CT95-0252 "Immunological engineering for generation of human therapeutic antibodies", total grant 18 MSEK
BIO4-CT96-0246 "Development of in vitro tests for drug allergenicity and B cell switching to IgE synthesis, total grant awarded 14 MSEK.
PL960389 Concerted action "The biotechnological use and further development of phage display", total grant awarded: 5 MSEK.
BMH4-97-2131 "Targeted anti-CD40 monoclonal antibodies for treatment of multiple sclerosis", total grant awarded: 6 MSEK
QLK3-2000-00273 "Human cell systems for predicting the allergenicity of genetically engineered proteins", total grant awarded 13 MSEK.

University Service:

Faculty representative in University policy issues:

- | | | |
|-----------|---|---------|
| 1997-1998 | representative in the working party forming the University policy for Patent and Commercialization of Research. | Faculty |
| 1997-1998 | Faculty representative in the working party forming the University policy for the University Research Policy | |
| 1998-2000 | Board member of the Biomedical Graduate School of Research | |

Executive examiner of Doctorate Degrees (Fakultetsopponent):

- 1991-1992 Per Borup Christensen (Doctorate Degree (Ph.D.)), Title: Human monoclonal antibodies against colo-rectal cancer associated antigens of potential value in diagnosis and therapy of cancer. Odense University, Denmark.
1998 Vigdis Luvrak (Ph.D.), Title: Filamentous phage peptide-display: A tool in the study of macromolecular interactions. Oslo University, Norway
2000 Ulrik Bjerl Nielsen (Ph.D.), Title: Antibody Targeted Breast Cancer Therapy. University of Copenhagen, Denmark.

Supervisor and Examiner for Graduate Degrees:

- 1988 Susanna A. Möller (Doctorate Degree in Biotechnology) (Tekn. Dr.), Title:

- Development of in vitro immunization for the production of mouse and human monoclonal antibodies.
- 1989 Ulf Schröder (Doctorate Degree in Biochemistry) (Tekn. Dr.), Title: Starch microspheres.
- 1990 Lena Danielsson (Doctorate Degree in Immunotechnology) (Tekn. Dr.), Title: Human monoclonal antibodies: In vitro immunization and cloning of DNA encoding variable regions.
- 1992 Mats Ohlin (Doctorate Degree in Immunotechnology) (Tekn. Dr.), Title: Human monoclonal antibody technology: A tool to investigate human antibody repertoires.
- 1993 Karin Kristensson (Doctorate Degree in Immunotechnology) (Tekn. Dr.), Title: T cell mediated effects on in vitro B cell response.
- 1994 Li-te Chin (Doctorate Degree in Immunotechnology) (Tekn. Dr.), Title: Site-directed in vitro immunization: A model for sequential antigen-specific activation of human B cells.
- 1995 Marta Dueñas (Doctorate Degree in Immunotechnology) (Tekn. Dr.), Title: Phage display and bacterial expression of antibody fragments.
- 1995 Cristina Mårtensson-Eriksson (Doctorate Degree in Immunotechnology) (Tekn. Dr.), Title: The Scid Mouse. A tool for generation of human monoclonal antibodies.
- 1995 Peter Ifversen, (Doctorate Degree in Immunotechnology) (Tekn. Dr.), Title: Human antibody technology. An evaluation of the Scid-hu-PBL model.
- 1996 Ann Catrin Simonsson Lagerkvist, (Doctorate Degree in Immunotechnology) (Tekn. Dr.), Title: In vitro generation and selection of antigen-specific antibodies
- 1996 Christina Furebring, (Doctorate Degree in Immunotechnology) (Tekn. Dr.), Title: Regulations of Ig genes.
- 1996 Ann Christin Malmberg, (Doctorate Degree in Immunotechnology) (Tekn. Dr.), Title: Molecular recognition in antibody engineering, Studies of recombinant and phage displayed antibodies.
- 1996 Marie Wallén Öhman, (Doctorate Degree in Immunotechnology) (Tekn. Dr.), Title: MHC class I induced apoptosis in hematopoietic cells.
- 1998 Sigurdur Ingvarsson, (Doctorate Degree in Immunotechnology) (Tekn. Dr.), Title: Signalling mechanisms in B cell differentiation: Studies on specific human immune response in vitro.
- 1998 Katarina Dahlenborg, (Doctorate Degree in Immunotechnology) (Tekn. Dr.), Title: Cellular and Molecular Aspects on Germinal Center Reactions
- 1998 Eva Andersson, (Doctorate Degree in Immunotechnology) (Tekn. Dr.), Title: Studies of T- and B cells for the generation of human antigen specific antibodies
- 1993 Nina Nilsson, (Doctorate Degree in Immunotechnology) (Tekn. Dr.), Title: In vivo and in vitro evolution of molecular mechanisms.
- 2000 Camilla Ottosson (Licentiat Degree in Immunotechnology)(Tekn. Lic.), Title: In vitro evolution by the FIND system and selection of novel phage antibodies.
- 2000 Magnus Strandh (Doctorate Degree in Immunotechnology) (Tekn. Dr.), Title: Insights into weak affinity antibody-antigen interactions.

- 2000 Pernilla Jirholt (Doctorate Degree in Immunotechnology) (Tekn. Dr.), Title: Generation and evolution of human antibody fragments – the CDR shuffling approach.

Qualifying Examination Committee (betygsnämnd):

- 1988 Michael Dohlsten (Doctorate Degree in Medical Science), Dept of Tumor Immunology, Title: Suppressive effects of histamine on T cell activation.
- 1988 Susanne Flygare (Doctorate Degree in Biochemistry), Dept of Pure and Applied Biochemistry, Title: I. Steroid transformation using immobilized cells. II. Affinity precipitation and magnetic aqueous two phase separation.
- 1988 Tyri Valdimarsdottir (Tekn. Lic.), Dept of Food Chemistry, Title: Quantitative determination of water soluble pentosans of rye grain. An immunochemical approach.
- 1989 Gunnar Hedlund (Doctorate Degree in Medical Science), Dept of Tumor Immunology, Title: Phenotype and function: Studies on T lymphocytes in rat and man.
- 1989 Bo Jansson (Doctorate Degree in Medical Science), Dept of Tumor Immunology, Title: Tumour associated antigens of chemically induced rat colon carcinomas defined by rat antibodies.
- 1990 Jan-Ingvar Jönsson (Doctorate Degree in Medical Science), Dept of Tumor Immunology, Title: Accessory molecules in T lymphocyte activation: The role of CD4 and CD8.
- 1991 Lars I. Andersson (Doctorate Degree in Biochemistry), Dept. of Pure and Applied Biochemistry, Title: Molecular recognition in synthetic polymers.
- 1992 P-O Ericsson (Doctorate Degree in Medical Science), Dept of Tumor Immunology, Title: Functional analysis of rat lymphocytes subsets.
- 1993 Karin Kronkvist (Doctorate Degree in Analytical Chemistry), Dept. of Analytical Chemistry, Title: Determination of steroids in biosamples at picomolar levels using enzyme immunochemical methods.
- 1994 Johan Hansson (Doctorate Degree in Medical Science), Dept of Tumor Immunology, Title: Activation and differentiation of cytotoxic T lymphocytes.
- 1995 Karin Johansson (Doctorate Degree in Medical Science), Dept of Immunology, Title: Analysis of Immunoglobulin gene expression: Focus on Oct2.
- 1996 Michael Garkavij (Doctorate Degree in Medical Science), Dept. of Radiophysics, Title: Improving radioimmunotargeting of tumors.
- 1998 Margareta Krook (Doctorate Degree in Biochemistry), Dept of Pure and Applied Biochemistry, Title: Combinatorial Methodology.
- 2000 Alexander Rosendahl (Doctorate Degree in Medical Science), Dept. Cell and Molecular Biology, Lund University, Title: Tumor Targeted Super Antigens.
- 2000 Gabriela Godaly (Doctorate Degree in Medical Science), Dept. of Medical Microbiology, Lund University, Title: Mechanisms of E. coli induced transepithelial neutrophil migration"
- 2000 Jesper Tordsson (Doctorate Degree in Medical Science), Dept of Tumor Immunology, Title: Identification of tumor associated antigens by antibodies phage selected using tumor cells and tissue sections.

International Promotion Review Boards:

- 1986 Prof. Irvin Goldstein, Department of Biological Sciences, University of Michigan, Ann Arbor, USA.
1991 Assistant Professor Steven Fount, Department of Pathology, Stanford University, Stanford, USA.
1997 Privaten Dozent for Stefan Dübel, Germany
1999 Senior Lecturer John Coleman, University of Liverpool, U.K.

Extra Curriculum Services:

- 1987-89 Grant reviewer for Bundesministerium für Wissenschaft und Forschung, Vienne, Austria
1990 Referee for the Swedish Nobel Committee.
1993 Grant reviewer for The Israel Science Foundation.
1994 Grant reviewer for Biotechnology and Biological Sciences Research Council (BBSRC) (U.K.).
1995 Grant reviewer For Human Frontier Science Program
1995- Grant Review Board for Teknikbröstförelsen (Foundation for Science Transfer between University & Industry)
1996 Grant reviewer for the Danish Cancer Society
1996 Grant reviewer for Pioneer Grant by NVO, The Netherlands

Editorial Services:

Editor-in-Chief:

1995-1998 IMMUNOTECHNOLOGY, Elsevier Science Publishers.

Editorial Board:

European R&D Database, Bowker Sauer.
Human Hybridomas and Antibodies (Editor-in-Chief: Mark Glassy), Butterworth Publishing
Journal of Clinical Laboratory Analysis (Editor-in-Chief: Ralph Reisfeld)
Serodiagnosis & Immunotherapy in Infectious Disease (Editor-in-Chief: James Burnie), Butterworth-Heinemann Ltd.

Editorial Reviewer for:

Proc. Natl Acad Sci. (USA), Nature Biotechnology, Eur. J. Immunol., Immunology, J. Immunol. Methods, Molec. Immunol., Anal. Biochem., Eur. J. Biochem., FEBS Letters, Glycoconjugate J., Arch. Biochem. Biophys, Hybridoma, Chimaoggia, Biotechniques etc.

Editor of:

"In Vitro Immunization in Hybridoma Technology", Elsevier Science Publishers, Amsterdam (1988), 317 pages.

- "Electromanipulation in Hybridoma Technology", Stockton Press (1989), co-editor: Inger Hagen, SI, Oslo, Norway.
 "Therapeutic Monoclonal Antibodies", Stockton Press (1990), co-editor: James W. Larrick, Genelabs Inc., California.
 "Antibody Engineering Manual", W.H. Freeman Publishing Co. 1st Ed., 1991.
 "Antibody Engineering Manual", Oxford University Press. 2nd Ed., 1995.

Invited speaker and chairman at scientific meetings:

- 1978 "Non-equilibrium enzyme immunoassay" at the Enzyme Labelled Immunoassay of Hormones and Drugs, Ulm, FRG.
 1983 "Mitogenic properties of PHA isolectins" at the Special Conference on Chemical Taxonomy, Molecular Biology and Biological Function of Lectins, Asilomar, California.
 1986 "In vitro immunization in hybridoma technology" at the XVII Meeting of Scandinavian Society for Immunology, Tampere, Finland. Chairman
 1986 "In vitro immunization for the production of monoclonal antibodies" at the Swedish Academy of Pharmaceutical Sciences, Stockholm.
 1986 "Hybridoma technology. Future developments in the production of murine and human monoclonal antibodies" at the Annual Meeting of the Swedish Society for Clinical Chemistry, Helsingborg, Sweden.
 1987 "In vitro immunization of peripheral blood lymphocytes for the production of human monoclonal antibodies" at the International Symposium on In Vitro Immunization in Hybridoma Technology, Tylösand, Sweden. Chairman.
 1987 "Human and mouse monoclonal antibodies produced by in vitro immunization" at The Annual Meeting of the Danish Society for Engineering, Copenhagen.
 1989 "Production and characterization of human monoclonal antibodies derived by in vitro immunization" at the International workshop on monoclonal antibody technology, Havana, Cuba.
 1989 "Human monoclonal antibodies. Production and therapeutic potentials" at the Second IRI Biotechnology Conference, Edinburgh, U.K.
 1989 "Strategies for the production of human monoclonal antibodies" at 2nd Japanese Assoc. for Animal Cell Culture, Tsukuba, Japan.
 1989 "Human monoclonal antibodies" at the Third Conference on Immunity to Cancer, Williamsburg, Virginia, USA.
 1989 "In vitro immunization for the production of human monoclonal antibodies" at the Contact Group on Monoclonal Antibodies (National Science Foundation), Liège, Belgium.
 1990 "Combination of cell and molecular biology approach for the production of human monoclonal antibodies", 8th European Immunology Meeting, Edinburgh, Scotland.
 1990 "In vitro immunization and human monoclonal antibodies", IBC Meeting, London, U.K.
 1990 "Scid-hu - Generation of human antibody specificities", Immunotechnology Conference, The Danish Society for Engineering, Copenhagen.

- 1991 "Advances in the application of monoclonal antibodies in clinical oncology", 8th International Hammersmith Meeting, Porto Carras, Halkidiki, Greece.
- 1992 "Tools for the production of human monoclonal antibodies", BIOTECH92, Genua, Italy.
- 1992 "The scid-hu model in human hybridoma technology", 2nd International Conference on Human Antibodies and Hybridomas, Cambridge, U.K.
- 1992 "Novel approaches for the production of human monoclonal antibodies", The 3rd International Conference on Biotechnology and Genetic Engineering, Havana, Cuba.
- 1992 "Human monoclonal antibodies: Tool and technologies", FEBS Meeting, Dublin, Ireland.
- 1992 "Manipulation of antibody specificities using scid-hu-mice", 3rd IBC Conference on Antibody Engineering, San Diego, USA.
- 1992 "Overview of issues, options & challenges for human monoclonal antibodies", IBC Conference on Human Monoclonal Antibodies, San Diego, USA
- 1993 "Recent developments in the generation of natural human monoclonal antibodies", Therapeutic Antibodies, Tokyo, Japan
- 1993 "Recent progress in the development of human monoclonal antibodies", 8th International conference on monoclonal antibody immunoconjugate for Cancer, San Diego, USA.
- 1993 "Antibody technology and phage display: Possibilities and limitations", Swedish Academy of Pharmaceutical Sciences, Stockholm, Sweden
- 1993 "Mimicking the humoral immune response: Linking antigen recognition and phage replication", 4th IBC Conference on Antibody Engineering, San Diego, USA.
- 1994 "Antibody Engineering", IMLAB Conference, Stockholm
- 1994 "SAP selection of phage displayed antibodies", Swedish Society for Biochemistry and Molecular Biology, Lund
- 1994 "SAP selection of phage displayed antibodies derived from in vitro immunized human B cells are affinity matured", European Immunology Meeting, Barcelona, Spain.
- 1994 "Mimicking the humoral immune response in vitro", Scheele Symposium, Uppsala, Sweden
- 1994 "Phage displayed antibodies derived from primary and secondary in vitro immunization" Biotechnologia 94, Habana, Cuba
- 1995 "SAP-Homogeneous selection of phage libraries", Nationaal Faag Display Platform, Maastricht, NL.
- 1995 "Phage display and its application to in vitro immunized human cells", 4th Int. Conference on Human Antibodies and Hybridomas, Amsterdam, The Netherlands
- 1995 "Homogeneous kinetic selection in antibody phage libraries", 23rd FEBS Meeting, Basel, Switzerland
- 1995 "Homogeneous selection principles in antibody phage libraries", Therapeutic Antibody Technology 95, San Fransisco, USA

- 1995 "Recombinant technologies for generation of human antibodies" Nobel Forum, Stockholm, Sweden
- 1996 "Homogeneous selection of phage libraries" Keystone Symposium, Taos, N.M., USA
- 1996 "Selection by bacteriophage infection. Technologies for gene identification", The Nordic Network Program on Immunotechnology, Helsinki, Finland.
- 1996 "Bacterial and phage display of molecular libraries: Design and applications", Oklahoma Medical Research Foundation, OKC, USA
- 1997 "Primary and secondary in vitro immunization of human B cells: Evaluated by phage display", University of Texas Southwestern Medical School, Dallas, TX.
- 1997 "Combination of bacterial and phage display for potential gene identification", IBC Conference "Exploiting display technologies in drug discovery, molecular evolution and vaccine development", Lake Tahoe, CA, USA.
- 1997 "Antibody based cancer therapy: A viable concept?" Oklahoma Health Science Center, OKC, OK
- 1997 "Selective Infection Mediated by Protein-Ligand interactions: Tapping the potential of molecular libraries for gene identification", Wennergrens Symposium on Chemical & Biological Combinatorial Libraries, Stockholm
- 1997 "Molecular libraries in functional genomics", Biotechnologia La Habana 1997, Havana, Cuba
- 1998 "Molecular libraries in functional genomics", Analytica 98, München.
- 1998 "Phage and Bacterial display", Workshop - European Science Foundation, Brussels
- 1998 "Design of molecular libraries in functional genomics", IBC Conference on Antibody Engineering, San Diego, USA
- 1999 "Deciphering the role of phage protein 3 during bacterial infection - implications for selective infection", Biotechnologia La Habana 1999, Havana, Cuba
- 2000 "n-CoDeR - A novel library design", Workshop on Biomolecular Recognition within Proteomics, Stockholm, Sweden
- 2000 "Protein chips for proteome analysis", Mini-symposium: Chips and Proteome Analysis, Malmö, Sweden
- 1991 "Postgenome research - A challenge " Biotech Forum, Ystad
- 1997 "Postgenomic challenges - Design of a novel antibody library concept", DeCode Genetics, Reykavik, Iceland.
- 2000 "Biomolecular recognition", VTT, Espoo, Finland.

Organizing Committees:

- 1986-
- 1989 Co-organizer of the Annual Meeting for "Lunda Immunologer", appr. 50 participants.
- 1987 Organizer of "International Symposium on In Vitro Immunization in Hybridoma Technology", Tylösand, Sweden, 85 participants (limited) from 16 countries.

- 1988 Scientific committee member of BioScience 88, Malmö, Sweden, appr. 700 participants.
- 1988 Co-organizer of "Electrofusion in Hybridoma Technology", Oslo, Norway 55 participants (limited) from 11 countries.
- 1989 Scientific committee member of BioScience 89, Malmö, Sweden, appr. 800 participants (chief organizer of a Monoclonal Antibody Workshop during BioScience).
- 1990 Scientific advisory committee of First Conference on Human Hybridomas and Monoclonal Antibodies, Orlando, Florida, USA.
- 1990 Workshop organizer/chairman at the 8th European Immunology Meeting, Edinburgh, Scotland.
- 1991 Workshop organizer/chairman at the 9th European Immunology Meeting, Helsinki, Finland.
- 1992 Scientific advisory committee of Second Conference on Human Hybridomas and Monoclonal Antibodies, Cambridge, U.K.
- 1992 Scientific advisory committee of the 3rd IBC Conference on Antibody Engineering and IBC Conference on Human Monoclonal Antibodies, San Diego, USA.
- 1993 Scientific advisory committee of Third Conference on Human Hybridomas and Monoclonal Antibodies, San Antonio, TX. USA.
- 1993 Scientific advisory committee of the 4th IBC Conference on Antibody Engineering, San Diego, USA.
- 1994 Workshop organizer/chairman at the 11th European Immunology Meeting, Barcelona, Spain.
- 1994 Scientific advisory committee of the Fourth Conference on Human Hybridomas and Monoclonal Antibodies, Amsterdam, The Netherlands.
- 1996 Scientific advisory committee of the Fifth Conference on Human Hybridomas and Monoclonal Antibodies, Israel

Society membership:

Scandinavian Society for Immunology

Swedish Immunology Society

American Association for the Advancement of Science - Member

New York Academy of Sciences

Miscellaneous:

Recipient of ICRETT Travel Award (International Union Against Cancer).

PUBLICATIONS

(Experimental papers, reviews, book chapters, patents)
Basic science in red /Applied science in black

Carl A.K. Borrebaeck

1. 1977 Mattiasson, B., Borrebaeck, C., Sanfridsson, B. & Mosbach, K.
Thermometric enzyme linked immunosorbent assay: TELISA.
Biochim. Biophys. Acta 483, 221-227.
2. 1978 Mattiasson B. & Borrebaeck, C.
An analytical flow system based on reversible immobilization of enzymes
and whole cells utilizing specific lectin-glycoprotein interaction.
FEBS Lett. 85, 119-123.
3. 1978 Borrebaeck, C., Börjesson, J. & Mattiasson, B.
Thermometric enzyme linked immunosorbent assay in continuous flow
systems: Optimization and evaluation using human serum albumin as a
model system.
Clin. Chim. Acta 86, 267-278.
4. 1978 Mattiasson, B., Svensson, K., Borrebaeck, C., Jonsson, S. & Kronvall, G.
Non-equilibrium enzyme immunoassay of gentamicin.
Clin. Chem. 24, 1770-1773.
5. 1978 Borrebaeck, C., Mattiasson, B. & Svensson, K.
A rapid non-equilibrium enzyme immunoassay for determining serum
gentamicin.
In: **Enzyme Labelled Immunoassay of Hormones and Drugs**, Ed. S.B.
Pal, Walter de Gruyter & Co., Berlin, pp. 15-27.
6. 1978 Mattiasson, B. & Borrebaeck, C.
Non-equilibrium, isokinetic enzyme immunoassay of insulin using reversibly
immobilized antibodies.
ibid pp. 91-105.
7. 1979 Borrebaeck, C.
Biospecific molecular interactions as a tool in analytical biochemistry;
Illustrated by antibody-antigen and lectin-carbohydrate reactions.
D.Sc. (Doctor of Science), University of Lund, Lund, Sweden.
Doctoral Thesis
8. 1979 Borrebaeck, C. & Mattiasson, B. Recent development in heterogeneous
enzyme immunoassay. (Review)

J. Solid Phase Biochem. 4, 57-67.

9. 1980 Borrebaeck, C. & Mattiasson, B.
A binding assay of carbohydrates and glycoproteins using a lectin electrode.
Protides of the Biological Fluids 27, 607-610.
10. 1980 Borrebaeck, C. & Mattiasson, B.
Competitive bindings studies of lectin-carbohydrate interactions using a lectin electrode.
Enzyme Engineering 5, 193-196.
11. 1980 Borrebaeck, C. & Mattiasson, B.
A study of structurally related binding properties of Concanavalin A using differential scanning calorimetry.
Eur. J. Biochem. 107, 67-71.
12. 1980 Borrebaeck, C. & Mattiasson, B.
Lectin-carbohydrate interactions studied by competitive enzyme inhibition assay.
Anal. Biochem. 107, 446-450.
13. 1980 Borrebaeck, C. & Börjesson, J.
A simple routine assay for serum urea using immobilized ureas.
Scand. J. Clin. Lab. Investig. 40, 169-172.
14. 1980 Borrebaeck, C.A.K. & Etzler, M.E.
A study of binding properties of the isolectins from the Dolichos biflorus plant using affinity electrophoresis.
FEBS Lett. 117, 237-240.
15. 1980 Etzler, M.E. & Borrebaeck, C.A.K.
Carbohydrate binding activity of a lectin-like glycoprotein from stems and leaves of Dolichos biflorus.
Biochem. Biophys. Res. Commun. 96, 92-97.
16. 1981 Mattiasson, B. & Borrebaeck, C.
Studies on lectin carbohydrate interactions using differential scanning calorimetry
In: **Lectins, Biology and Biochemistry**, Ed. T.C. Bøg-Hansen, Walter de Gruyter & Co., Berlin, pp. 199-206.
17. 1981 Mattiasson, B. & Borrebaeck, C.
Novel approaches to enzyme immunoassay. (Review)
In: **Enzyme Based Immunoassay**, CRC Press, Miami U.S.A., Ed. E.T. Maggio, pp. 213-248.

18. 1981 Axelsson, B., Eriksson, H., Borrebaeck, C., Mattiasson, B. & Sjögren, H.O. Liposome immunoassay (LIA). Use of membrane antigens inserted into labeled vesicles as targets in immunoassay.
J. Immunol. Methods. 41, 351-363.
19. 1981 Etzler, M.E., Gupta, G. & Borrebaeck, C.A.K.
Carbohydrate binding properties of the Dolichos biflorus lectin and its subunits
J. Biol. Chem. 256, 2367-2370.
20. 1981 Borrebaeck, C.A.K., Lönnnerdal, B. & Etzler, M.E.
The metal ion content of the Dolichos biflorus lectin and the effect of divalent cations on the lectin activity.
Biochemistry 20, 4119-4122.
21. 1981 Borrebaeck, C.A.K. & Etzler, M.E.
Production and characterization of a monoclonal antibody against the seed lectin of the Dolichos biflorus plant.
J. Biol. Chem. 256, 4723-4725.
22. 1981 Borrebaeck, C.A.K., Lönnnerdal, B. & Etzler, M.E.
Metal chelate affinity chromatography of Dolichos biflorus seed lectin and its subunits.
FEBS Lett. 130, 194-196.
23. 1982 Borrebaeck, C.A.K. & Etzler, M.E.
Mitogenic properties of two carbohydrate binding proteins from the Dolichos biflorus plant.
FEBS Lett. 145, 8-10.
24. 1983 Borrebaeck, C.A.K. & Mattiasson, B.
Distribution of a lectin in the tissues of Phaseolus vulgaris.
Physiol. Plant. 58, 29-32.
25. 1983 Borrebaeck, C.A.K.
In vitro immunization for the production of specific lymphocyte hybridomas.
Scand. J. Immunol. 18, 9-12.
26. 1983 Lönnnerdal, B., Borrebaeck, C.A.K., Etzler, M.E. & Ersson, B.
Dependence of cations for the binding activity of lectins as determined by affinity electrophoresis.
Biochem. Biophys. Res. Commun. 115, 1069-1074.
27. 1983 Mattiasson, B., Borrebaeck, C.A.K., Sanfridsson, B. & Mosbach, K. Assay

and device for determining the concentration of antigen in a biological system. Swedish Patent No. 7612556-6.

28. 1983 Schöder, U. & Borrebaeck, C.A.K.
Magnetic carbohydrate particles as carriers for affinity separation purposes, e.g. cell separation.
Patent pending (PCT WO 83/03426).
29. 1983 Borrebaeck, C.A.K.
In vitro immunization of mouse spleen cells and the production of monoclonal antibodies.
Acta Chem. Scand. B37, 647-648.
30. 1983. Borrebaeck, C.A.K.
Immunoteknologi-Monoklonala antikroppar, (eng. Immunotechnology-Monoclonal antibodies). (Review)
ORDO 6, 12-14.
31. 1984 Glad, C. & Borrebaeck, C.A.K.
The relation between metal ion content and mitogenicity of PHA-L4 as illustrated by agarose electrophoresis.
In: Plant Lectins, Eds. Goldstein, I.J., & Etzler, M.E., Alan R. Liss, Inc., New York, pp. 251-252.
32. 1984 Borrebaeck, C.A.K. & Glad, C.
Microheterogeneity of the PHA isolectins.
ibid, 253-254.
33. 1984. Borrebaeck, C.A.K., Soares, J. & Mattiasson, B.
Fractionation of glycoproteins according to lectin affinity and molecular size using a HPLC system with sequentially coupled columns.
J. Chromatogr. 284, 187-192.
34. 1984 Borrebaeck, C.A.K.
Detection and characterization of a lectin from non-seed tissue of the Phaseolus vulgaris plant.
Planta 161, 223-228.
35. 1984 Wallin, H., Borrebaeck, C.A.K., Glad, C., Mattiasson, B. & Jergil, B.
Enzym immunoassay of benzo(a)pyrene conjugated to DNA, RNA and microsomal proteins using a monoclonal antibody.
Cancer Lett. 22, 163-170.
36. 1984 Glad, C. & Borrebaeck, C.A.K.
Affinity of phytohemagglutinin (PHA) isolectin for serum proteins and

regulation of the lectin induced lymphocyte transformation.
J. Immunol. 133, 2126-2132.

37. 1984 Borrebaeck, C.A.K., Mattiasson, B. & Nordbring-Hertz, B.
 Isolation and partial characteriation of a carbohydrate binding protein from a
 nematode-trapping fungus.
J. Bacteriology 159, 53-56.
38. 1984 Borrebaeck, C.A.K.
 Dependence on T-cell-replacing-factor and immunogenic dose for the
 production of monoclonal antibodies using the in vitro immunization
 technique.
Mol. Immunol. 21, 841-845.
39. 1985 Möller, S.A. & Borrebaeck, C.A.K.
 A microfilter assay for the detection of antibody producing cells in vitro.
 In: *Rapid Methods and Automation in Microbiology and Immunology*,
 Ed. K.-O. Habermehl, Springer Verlag, Berlin, pp. 123-128.
40. 1985 Borrebaeck, C.A.K., Mattiasson, B. & Nordbring-Hertz, B.
 A fungal lectin and its apparent receptors on a nematode surface.
FEMS Letters 27, 35-39.
41. 1985 Möller, S.A. & Borrebaeck, C.A.K.
 A filter immuno-plaque assay for the detection of antibody producing cells
in vitro.
J. Immunol. Methods 79, 195-204.
42. 1985 Borrebaeck, C.A.K. & Linsefors, L.
 Hormonal regulation of the lectin biosynthesis in callus culture of the
Phaseolus vulgaris plant.
Plant Physiol. 79, 659-662.
43. 1986 Danielsson, L., Möller, S.A. & Borrebaeck, C.A.K.
 Factor dependent Con A activation of B lymphocytes.
 In: *Lectins, Biology, Biochemistry, Clinical Biochemistry*, vol. 5, Ed.
 T.C. Bøg-Hansen, Walter de Gruyter Co, Berlin, pp. 347-355.
44. 1986 Möller, S.A., Danielsson, L. & Borrebaeck, C.A.K.
 Concanavalin A induced B cell activation mediated by allogeneically
 derived helper factors.
Immunology 57, 387-393.
45. 1986 Borrebaeck, C.A.K. & Möller, S.A.
In vitro immunization. Effect of growth and differentiation factors on

antigen-specific B cell activation and the production of monoclonal antibodies to autologous and weak immunogens
J. Immunol. 136, 3710-3715.

46. 1986 Glad, C. & Borrebaeck, C.A.K.
 The relation between metal ion content and mitogenicity of PHA-L4 isolectin as determined by agarose electrophoresis.
J. Immunol. Methods 87, 149-153.
47. 1986 Borrebaeck, C.A.K. & Rougé, P.
 Mitogenic properties of structurally related Lathyrus lectins.
Arch. Biochem. Biophys. 248, 30-34.
48. 1986 Borrebaeck, C.A.K.
 In vitro immunization for the production of murine and human monoclonal antibodies - Present status. (Review).
Trends in Biotech. (TIBS) 4, 147-153.
49. 1986 Danielsson, L., Möller, S.A. & Borrebaeck, C.A.K. Immunteknologi - ett expansivt immunologiskt forskningsområde, (eng. Immunotechnology - an expansive immunological research area). (Review).
ORDO 3, 27-30.
50. 1986 Schröder, U., Segren, S., Gemnefors, C., Hedlund, G., Jansson, B., Sjögren, H-O. & Borrebaeck, C.A.K. Magnetic carbohydrate nanoparticles for affinity cell separation
J. Immunol. Methods. 93, 45-53.
51. 1987 Borrebaeck, C.A.K. & Schön, A.
 Antiproliferative response of human leukemic cell lines. PHA induced inhibition of DNA synthesis and cellular metabolism.
Cancer. Res. 47, 4345-4350.
52. 1987 Danielsson, L., Möller, S.A. & Borrebaeck, C.A.K.
 Effect of cytokines on specific in vitro immunization of human peripheral B lymphocytes against T cell dependent antigens.
Immunology 61, 51-55.
53. 1987 Borrebaeck, C.A.K., Danielsson, L. & Möller, S.A.
 Human monoclonal antibodies produced by primary in vitro immunization of peripheral blood lymphocytes.
Biochem. Biophys. Res. Commun. 148, 941-946.
54. 1987 Rougé, P., Borrebaeck, C.A.K., Richardson, M. & Yarwood, A.
 Structure-function relationship among Lathyrus lectins.

Glycoconj. J. 4, 371-378.

55. 1987 Borrebaeck, C.A.K., Danielsson, L. & Möller, S.A.
Method of producing human monoclonal antibodies and kit therefor.
Patent (PCT/SE87/00389)
56. 1987 Borrebaeck, C.A.K.
Development of in vitro immunization in murine and human hybridoma technology. (Review).
J. Pharm. Biomed. Analysis. 5, 783-792.
57. 1987 Borrebaeck, C.A.K., Bristulf, J. & Jergil, B.
Antiproliferative response of human leukemic cells. Modulation of cytosolic protein kinase C activity by phytohemagglutinin.
Cancer Lett. 38, 181-189.
58. 1988 Borrebaeck, C.A.K.
Critical appraisal of the in vitro immunization technology for the production of mouse and human monoclonal antibodies. (Review).
Advanced Drug Delivery Reviews 2, 143-165.
59. 1988 Möller, S.A. & Borrebaeck, C.A.K.
Development of an in vitro immunization technique for the production of antibodies using small amounts of antigen and weak immunogens. (Review)
In: In Vitro Immunization in Hybridoma Technology, Progress in Biotechnology, Vol. 5, Ed. C.A.K. Borrebaeck, Elsevier Science Publisher, Amsterdam, pp. 3-22.
60. 1988 Borrebaeck, C.A.K.
Human monoclonal antibodies produced from primary in vitro immunized leucine methyl ester treated peripheral blood lymphocytes. (Review).
ibid. pp. 209-230.
61. 1988 Wallén, M., Mattiasson, B. & Borrebaeck, C.A.K.
Dose dependent modulation of monoclonal antibody affinities by in vitro immunization.
ibid. pp. 85-94.
62. 1988 Borrebaeck, C.A.K., Danielsson, L. & Möller, S.A.
Human monoclonal antibodies produced by primary in vitro immunization of peripheral blood lymphocytes.
Proc. Natl. Acad. Sci (USA) 85, 3995-3999.
63. 1988 Dahmus, M., Laybourn, P. & Borrebaeck, C.A.K.
Production of monoclonal antibodies against electrophoretically purified

RNA polymerase II subunits using in vitro immunization.
Mol. Immunol. 25, 997-1003.

64. 1988 Borrebaeck, C.A.K.
 Human monoclonal antibodies produced by in vitro immunization.
 (Review).
 Immunol. Today 9, 355-359.
65. 1989 Borrebaeck, C.A.K. & Glad, C.
 Cross-reactivity of mouse monoclonal antibodies produced by in vitro or in vivo immunization.
 Immunol. Lett. 20, 255-261.
66. 1989 Borrebaeck, C.A.K. & Carlsson, R.
 Lectins as mitogens. (Review).
 Advances in Lectin Research, vol. 2, Ed. H. Franz, Springer Verlag, Berlin, 10-27.
67. 1989 Ohlin, M., Broliden, P.-A., Danielsson, L., Wahren, B., Rosen, J., Jondal, M. & Borrebaeck, C.A.K.
 Human monoclonal antibodies against a recombinant HIV envelope- antigen produced by primary in vitro immunization. Characterization and epitope mapping.
 Immunology 68, 325-331.
68. 1989 Ohlin, M., Danielsson, L., Carlsson, R. & Borrebaeck, C.A.K.
 The effect of leucyl-leucine methyl ester on proliferation and Ig-secretion of EBV-transformed human B lymphocytes.
 Immunology 66, 485-490.
69. 1989 Larrick, J.W., Danielsson, L., Brenner, C., Abrahamsson, M., Fry, K. & Borrebaeck, C.A.K.
 Rapid cloning of rearranged immunoglobulin genes from human hybridoma cells using mixed primers and the polymerase chain reaction.
 Biochem. Biophys. Res. Commun. 160, 1250-1254
70. 1989 Borrebaeck, C.A.K.
 Humana Monoklonala Antikroppar - Nya Terapeutiska Möjligheter.
 (Review)
 J. Swed. Medical Assoc. (Läkartidningen) 86, 1692-95.
71. 1989 Borrebaeck, C.A.K.
 Strategy for the production of human monoclonal antibodies using in vitro activated B cells. (Review)
 J. Immunol. Methods 123, 157-165.

72. 1989 Carlsson, R., Glad, C. & Borrebaeck, C.A.K.
Monoclonal antibodies into the '90s: The all-purpose tool (Review)
Bio/technology 7, 567-573.
73. 1989 Larrick, J.W., Danielsson, L., Brenner, C., Wallace, E., Abrahamsson, M., Fry, K. & Borrebaeck, C.A.K.
Polymerase chain reaction using mixed primers. Cloning of human monoclonal antibody variable region genes from single hybridoma cells.
Bio/technology 7, 934-938.
74. 1990 Möller, S.A., Birkedal, S. & Borrebaeck, C.A.K.
High affinity human IgM monoclonal antibodies against *Mycoplasma hominis*.
J. Clin. Lab. Anal. 4, 390-395.
75. 1990 Zhang, Xiu-mei & Borrebaeck, C.A.K.
Human monoclonal antibodies. In vitro immunization of human B lymphocytes with cultured melanoma cells (SK-MEL-28)
Hum Antibod. Hybridomas 1, 42-46.
76. 1990 Borrebaeck, C.A.K., Danielsson, L., Ohlin, M., Carlsson, J. & Carlsson, R.
The use of in vitro immunization, cloning of variable regions, and SCID mice for the production of human monoclonal antibodies. In: *Therapeutic Monoclonal Antibodies* (Borrebaeck, C.A.K. & Larrick, J.W., Eds.), Stockton Press, New York. pp.1.
77. 1991 Ohlin, M., Sundqvist, V.-A., Gilliam, G., Ruden, U., Gombert, F.O., Wahren, B. & Borrebaeck, C.A.K.
Characterization of human monoclonal antibodies directed against the pp65 KD matrix antigen of human cytomegalovirus .
Clin. Exp. Immunol. 84, 508-514.
78. 1991 Wallen, M. & Borrebaeck, C.A.K.
The affinity repertoire of monoclonal antibodies obtained by primary or secondary in vitro immunization.
Hybridoma 10, 333-345.
79. 1991 Danielsson, L., Furebring, C., Ohlin, M., Hultman, L., Abrahamson, M., Carlsson, R. & Borrebaeck, C.A.K.
Human monoclonal antibodies with different finespecificity for digoxin derivatives: Cloning of heavy and light chain variable region sequences.
Immunology, 74, 50-54.

80. 1991 Sjögren-Jansson, E., Ohlin, M., Borrebaeck, C.A.K. & Jeansson, S.
Production of human monoclonal antibodies in dialysis tubing.
Hybridoma 10, 411-419.
81. 1991 Jansson, B. & Borrebaeck, C.A.K.
The human repertoire of antibody specificities against Thomsen- Friedenreich
and Tn carcinoma associated antigens as defined by human monoclonal
antibodies.
Cancer Immunol. Immunotherapy 34, 294-298.
82. 1991 Simonsson, A.-C. & Borrebaeck, C.A.K.
In vitro immunization of human B lymphocytes. MAPPING of human
lymphokine specific mRNA and the effect of recombinant factors.
Hum. Antibod. Hybridomas 2, 148-154.
83. 1991 Ohlin, M. & Borrebaeck, C.A.K.
Production of human monoclonal antibodies.
In: *Methods of Immunological Analysis*, Vol. 2 (Masseyeff, R. Ed.),
Chapter 4, VCH Verlagsgesellschaft mbH, Weinheim, FRG.
84. 1991 Danielsson, L. & Borrebaeck, C.A.K.
Amplification of rearranged Ig variable region DNA from single cells, In:
Antibody Engineering (Borrebaeck, C.A.K. Ed.), W.H. Freeman
Publishing Co., New York. pp.89-102.
85. 1992 Carlsson, R., Mårtensson, C., Kalliomäki, S., Ohlin, M. & Borrebaeck,
C.A.K.
Human peripheral blood lymphocytes transplanted into SCID mice constitute
an in vivo culture system exhibiting several parameters found in a normal
humoral immune response and are the source of immunocytes for the
production of human monoclonal antibodies.
J. Immunol. 148, 1065-1071.
86. 1992 Kristensson, K., Borrebaeck, C.A.K. & Carlsson, R.
Human CD4+ T cells expressing CD45RA acquire the lymphokine gene
expression of CD45RO+ T helper cells after activation in vitro.
Immunology 76, 103-109.
87. 1992 Malmberg, A.-C., Michaelsson, A., Ohlin, M., Jansson, B. & Borrebaeck,
C.A.K.
Real time analysis of antibody - antigen reaction kinetics.
Scand. J. Immunol. 35, 643-650.
88. 1992 Borrebaeck, C.A.K. & Ohlin, M.
In vitro immunization of peripheral lymphocytes for the production of

human monoclonal antibodies.

In: **Cell & Tissue Culture: Laboratory Procedures**, (Griffiths, J.B., Doyle, A., Newell, D.G., Eds.), John Wiley & Sons, Ltd., U.K.

89. 1992 Ohlin, M., Hinkula, J., Broliden, P.-A., Grunow, R., Borrebaeck, C.A.K. & Wahren, B.
Human monoclonal antibodies produced from normal, HIV-1 seronegative donors and specific for glycoprotein gp120 of the HIV-1 envelope.
Clin. Exp. Immunol. 84, 508-514.
90. 1992 Borrebaeck, C.A.K., Malmborg, A.-C., Furebring, C., Michaelsson, A., Ward, S., Danielsson, L. & Ohlin, M.
Kinetic analysis of recombinant antibody-antigen interactions: Relation between structural domains and antigen binding.
Bio/Technology 10, 697-698.
91. 1992 Fernandez-de-Cossio, Ohlin, M., Llano, M., Selander, B., Cruz, S., del Valle, J. & Borrebaeck, C.A.K.
Human monoclonal antibodies against an epitope on the class 5c outer membrane protein common to many pathogenic strains of Neisseria meningitides.
J. Infect. Dis. 166, 1322-1328.
92. 1992 Söderlind, E., Simonsson, A.-C., & Borrebaeck, C.A.K.
Phage display technology in antibody engineering: Design of phagemid vectors and in vitro maturation systems.
Immunol. Rev. 130, 109-124.
93. 1992 Ohlin, M., Kristensson, K., Carlsson, R., & Borrebaeck, C.A.K.
Epstein-Barr Virus-induced transformation of human B lymphocytes: The effect of L-Leucyl-L-Leucine methyl ester on inhibitory T cell populations.
Immunol. Lett. 34, 221-228.
94. 1993 Borrebaeck, C.A.K., Mårtensson, C., Ifversen, P. & Carlsson, R.
Evaluation of the scid-hu mouse as a model to generate human monoclonal antibodies.
In: **Monoclonal Antibodies. Applications in Clinical Oncology** (Epenetos, A., Ed.), Chapman & Hall Medical, London, Chap. 50, pp. 481-493.
95. 1993 Ohlin, M., Sundqvist, V.A., Mach, M., Wahren, B., & Borrebaeck, C.A.K.
Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gb) studied by human monoclonal antibodies.

J. Virology 67, 703-710.

96. 1993 Söderlind, E., Simonsson, A.-C., Dueñas, M., Malmberg, A.-C., Ayala, M., Danielsson, L., & Borrebaeck, C.A.K.
Chaperonin assisted phage display of antibody fragments on filamentous bacteriophages.
Bio/technology 11, 503-507.
97. 1993 Ifversen, P., Zhang, X.-m., Ohlin, M., Zeuthen, J., & Borrebaeck, C.A.K.
Effect of cell-derived growth factors and cytokines on the clonal outgrowth of EBV infected cells and established lymphoblastoid cell lines.
Hum Antibod. Hybridomas 4, 115-123.
98. 1993 Ayala Avila, M., Vázquez, J., Danielsson, L., Fernandez de Cossio, M.-E., & Borrebaeck, C.A.K.
Nucleotide sequence determination of variable region genes of two human monoclonal antibodies against *Neisseria meningitidis*.
Gene 127, 273-274.
99. 1993 Wallén Öhman, M., Lönnbro, P., Schön, A. & Borrebaeck, C.A.K.
Antibody-induced apoptosis in a human leukemia cell line is energy dependent: Thermochemical analysis of cellular metabolism.
Cancer Lett. 75, 103-109.
100. 1993 Borrebaeck, C.A.K., Malmberg, A.-C., & Ohlin, M.
Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?
Immunol. Today 14, 477-479.
101. 1994 Chin, L.-T., Hinkula, J., Ohlin, M., Wahren, B., & Borrebaeck, C.A.K.
Site-directed primary in vitro immunization: Production of HIV-1 neutralizing human monoclonal antibodies from lymphocytes obtained from seronegative donors. *Immunology* 81, 428-434.
102. 1994 Wallén, M. & Borrebaeck, C.A.K.
A cell surface antigen (BAL) defined by a mouse monoclonal antibody inducing apoptosis in a human acute lymphocytic leukemia cell line.
Int. J. Cancer 57, 544-552.
103. 1994 Chin, L.-t., Ifversen, P., Kristensson, K., Wahren, B., Carlsson, R., & Borrebaeck, C.A.K.
Human Th0-type T helper cell clone supports antigen-specific immunoglobulin production in scid/beige-hu mice.
Scand. J. Immunol. 40, 529-534.

104. 1994 Ohlin, M., & Borrebaeck, C.A.K.
Flow cytometric analysis of the stability of antibody production by human x human x mouse heterohybridoma subclones.
J. Immunol. Methods 170, 75-82.
105. 1994 Ohlin, M. & Borrebaeck, C.A.K.
Immunotechnology (invited review).
Immunol. Today 15, 499-500.
106. 1994 Ohlin, M., Owman, H., Rioux, J.D., Newkirk, M.M. and Borrebaeck, C.A.K.
Restricted variable region gene usage and possible rheumatoid factor relationship among human monoclonal antibodies specific for the AD-1 epitope on cytomegalovirus glycoprotein B.
Mol. Immunol. 31, 983-91.
107. 1994 Kristensson, K., Kristensen, L., Borrebaeck, C.A.K., & Carlsson, R.
Activation of CD4+CD45RA+ T cells using B cells as accessory cells.
Immunol. Letters 39, 223-229.
108. 1994 Dueñas, M., Vázquez, J., Ayala, M., Söderlind, E., Ohlin, M., Perez, L., & Borrebaeck, C.A.K.
Intra- and extracellular expression of a scFV antibody fragment in *E. coli*: Effect of bacterial strains and pathway engineering using GroES/L chaperonins.
Biotechniques 16, 476-483.
109. 1994 Dueñas, M. & Borrebaeck, C.A.K.
Clonal selection and amplification of phage displayed antibodies by linking antigen recognition and phage replication
Bio/technology 12, 999-1002.
110. 1994 Mårtensson, C., Kristensson, K., Kalliomäki, S., Borrebaeck, C.A.K., & Carlsson, R.
Antigen-specific human immunoglobulin production in SCID mice transplanted with human peripheral lymphocytes is dependent on CD4+CD45+R0+ T cells.
Immunology 83, 171-179.
111. 1995 Söderlind, E., Dueñas, M. & Borrebaeck, C.A.K.
Chaperonins in phage display of antibody fragments
In: *Practical Antibody Engineering and Catalytic Antibodies, Methods in Molecular Biology*, Humana Press (Walker, J., Ed.), vol.51, Chapt 23, pp. 343-353.

112. 1995 Chin, L.-t., Dueñas, M., Levi, M., Hinkula, J., Wahren, B. & Borrebaeck, C.A.K.
Molecular characterization of a human anti-HIV 1 monoclonal antibody revealed a CD26 related motif in CDR2
Immunol. Letters 44, 25-30.
113. 1995 Ifversen, P., Mårtensson, C., Danielsson, L., Ingvar, C., Carlsson, R., Borrebaeck, C.A.K.
Induction of primary antigen-specific responses in Scid-hu-PBL by coupled T-B epitopes.
Immunology 84, 111-116.
114. 1995 Dueñas, M. & Borrebaeck, C.A.K.
Novel helper phage design: Intergenic region affects the assembly of bacteriophages and the size of antibody libraries
FEMS Microbiology Letters 125, 317-322.
115. 1995 Dueñas, M., Ayala, M., Vazquez, J., Ohlin, M., Söderlind, E., Borrebaeck, C.A.K., & Gavilondo, J.V.
A point mutation in murine immunoglobulin V-region strongly influences the antibody yield in *Escheria coli*.
Gene 158, 61-66.
116. 1995 Malmberg, A.-C. & Borrebaeck, C.A.K.
BIAcore™ as a tool in antibody engineering
J. Immunol. Methods 183, 7-13.
117. 1995 Rioux, J.D., Ohlin, M., Borrebaeck, C.A.K. & Newkirk, M.M.
Molecular Characterization of human monoclonal antibodies specific for human cytomegalovirus: Relationship of variable region sequence to antigen specificity and rheumatoid factor-associated idiotype expression
Immunol. Infect. Disease 5, 43-52.
118. 1995 Chin, L.-t., A.-C. Malmberg, K. Kristensson, J. Hinkula, B. Wahren, and C.A.K. Borrebaeck.
Mimicking the humoral immune response in vitro results in antigen-specific isotype switching supported by autologous T helper cells: Generation of human HIV-1 neutralizing IgG monoclonal antibodies from naive donors.
Eur. J. Immunol. 25, 657-663.
119. 1995 Söderlind, E., Vergeles, M., & Borrebaeck, C.A.K.
Domain libraries: Synthetic diversity for *de novo* design of antibody V-regions.
Gene 160, 269-272.

120. 1995 Simonsson Lagerkvist, A.C., Furebring, C. & Borrebaeck, C.A.K.
Single antigen-specific B cells used to generate Fab fragments using CD40 mediated amplification or direct PCR cloning
Biotechniques 18, 862-869.
121. 1995 Andersson, E., Ohlin, M., Borrebaeck, C.A.K. & Carlsson, R.
CD4+CD57+ T cells derived from peripheral blood do not support immunoglobulin production by B cells.
Cell. Immunol. 163, 245-253
122. 1995 Ingvarsson, S., Simonsson Lagerkvist, A.C., Mårtensson, C., Granberg, U., Ifversen, P., Borrebaeck, C.A.K. & Carlsson, R.
Antigen-specific activation of B cells in vitro after recruitment of T cell help with superantigen.
Immunotechnology 1, 29-39.
123. 1995 Ingvarsson, S., Simonsson Lagerkvist, A.C., Carlsson, R. & Borrebaeck, C.A.K.
Stimulation of human peripheral lymphocytes via CD3 and soluble antigen abrogates specific antibody production by reducing memory B cell numbers.
Scand. J. Immunol. 42, 331-336.
124. 1995 Rioux, J.D., Brodeur, B.R., Larose, Y., Ohlin, M., Borrebaeck, C.A.K. & Newkirk, M.
Generation of diversity in a human anti-viral response
Annals New York Acad. Sci. 764, 381-83.
125. 1995 Mårtensson, C., Ifversen, P., Borrebaeck, C.A.K. & Carlsson, R.
Enhancement of specific immunoglobulin production in SCID-hu-PBL mice after in vitro priming of human B cells with superantigen.
Immunology 86, 224-230.
126. 1995 Ohlin, M., Plachter, B., Sundqvist, V.-A., Middeltorp, J.M., Steenbakkers, P.G.A and Borrebaeck, C.A.K.
Human antibody reactivity against the lower matrix protein (pp65) produced by cytomegalovirus.
Clin. Diagn. Lab. Immunol. 2, 325-29.
127. 1995 Ohlin, M., Owman, H., Mach, M., Sundqvist, V.A. & Borrebaeck, C.A.K.
Light chain shuffling of a cytomegalovirus glycoprotein B-specific antibody results in a modified epitope specificity
Scand. J. Infect. Dis. Suppl. 99, 24.
128. 1995 Malmberg, A.-C., Johansson, K., Sigvardsson, M., Borrebaeck, C.A.K., & Leandersson, T.

Real-Time analysis of Oct protein/octamer interaction and transcription complex assembly.

Mol. Immunol. 32, 1429-1442.

129. 1995 Wahren, B., Hinkula, J., Ljungdal, Ståhle, E., Borrebaeck, C.A.K., Schwartz, S. & Wigzell, H.
Nucleic acid vaccination with HIV regulatory genes
Ann. NY Acad. Sci. 772, 278-281.
130. 1996 Schoppel, K., Hassfurth, E., Britt, W., Ohlin, M., Borrebaeck, C.A.K. & Mach, M.
Antibodies specific for the antigenic domain 1 (AD-1) of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures
Virology, 216, 133-145
131. 1996 Ohlin, M., Owman, H., Mach, M. & Borrebaeck, C.A.K.
Light chain shuffling of a high affinity antibody results in a drift in epitope recognition
Mol. Immunol. 33, 47-56.
132. 1996 Dueñas, M., Malmberg, A.-C., Casalvilla, R. and Borrebaeck, C.A.K.
Selecting of phage displayed antibodies based on kinetic constants.
Mol. Immunol. 33, 279-285
133. 1996 Andersson E, Dahlenborg K, Ohlin M, Borrebaeck CAK and Carlsson R.
Immunoglobulin production induced by GC-derived helper T cells in vitro require addition of exogenous IL-2. Cell. Immunol. 169, 166-173.
134. 1996 Ohlin, M. & Borrebaeck, C.A.K.
Characterization of human antibody repertoires following active immune responses in vivo
Mol. Immunol. 33, 583-592.
135. 1996 Ifversen, P & Borrebaeck, C.A.K.
SCID-hu-PBL: A model for making human antibodies?
Sem. Immunol. 8, 243-248.
136. 1996 Arulampalam, V., Furebring, C., Samuelsson, A., Lendahl, U., Borrebaeck, C.A.K., Lundkvist, I., & Pettersson, S.
Elevated expression levels of an immunoglobulin transgene in mice links the IgH 3' enhancer to the regulation of IgH expression.
Int. Immunol. 8, 1149-1157.
137. 1996 Ohlin, M. & Borrebaeck, C.A.K.
Low affinity antibody binding of an *E. coli* -derived component

FEMS Immunol. Med. Microbiol. 13, 161-168.

138. 1996 Dueñas, M., Chin, L.-t., Malmborg, A.-C., Casavilla, R., Ohlin, M. & Borrebaeck, C.A.K.
In vitro immunization of naive human B cells yields high affinity IgG antibodies as illustrated by phage display.
Immunology 89, 1-7.
139. 1996 Ohlin M, Furebring C and Borrebaeck CAK. Low affinity binding of human immunoglobulin variable domains. A new superantigen in *Escherichia coli*? In: Human B-cell superantigens. (Ed. M. Zouali). R. G. Landes Bioscience Publishers, Austin, TX, USA pp 113-119.
140. 1996 Malmborg, A.-C., Dueñas, M., Ohlin, M., Söderlind, E. & Borrebaeck, C.A.K.
Kinetic selection of phages from phage displayed antibody libraries using BIAcore™ biosensor
J. Immunol. Methods 198, 51-57.
141. 1997 Ohlin, M., Silvestri, M., Sundqvist, V.-A. & Borrebaeck, C.A.K.
Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based technique.
Clin. Diagn. Lab. Immunol. 4, 107-111.
142. 1997 Dahlenborg, K, Pound, J.D., Gordon, J., Borrebaeck, C.A.K. & Carlsson, R.
Terminal differentiation of human germinal center B cell in vitro
Cell. Immunol. 175, 141-149.
143. 1997 Duenas, M., Casavilla, R., Malmborg, A-C., Chin. L-t., Ohlin, M. & Borrebaeck, C.A.K.
The SAP as a homogenous and kinetic based selection systems for active proteins in combinatorial libraries.
Biotec. Aplicada 14, 51-52.
144. 1997 Furebring, C., Ohlin, M., Pettersson, S. & Borrebaeck, C.A.K.
Evaluation of novel control elements by construction of eukaryote expression vector
Gene 188, 191-198.
145. 1997 Wallén-Öhman, M., Larrick, J.W., Carlsson, R. & Borrebaeck, C.A.K.
Ligation of MHC Class I induces apoptosis in human pre-B cell lines, in promyelocytic cell lines and in CD40 stimulated mature B cells.
Int. Immunol. 9, 599-606.

146. 1997 Zafiropoulos, A., Andersson, E., Krambovitis, E. & Borrebaeck, C.A.K.
Induction of antigen-specific isotype switch by in vitro immunization of human naive B lymphocytes.
J. Immunol. Methods 200, 181-190.
147. 1997 Nilsson, N., Wallen Öhman, M., Ohlin, M. & Borrebaeck, C.A.K.
Altered gene expression associated with apoptosis in a pre-B leukemic cell line followed cross-linking of MHC class I.
Exp. Cell Research 231, 190-197.
148. 1997 Borrebaeck, C.A.K., Söderlind, E., Frost, L.S. & Malmberg, A-C.
Combining bacterial and phage display: Tapping the potential of molecular libraries for gene identification. In: *Display Technologies. Novel targets and strategy* (eds Guttry, P. & Savage, L.M.) International Business Communication Press, pp. 197-208.
149. 1997 Malmberg, A.-C., Söderlind, E., Frost, L. & Borrebaeck, C.A.K.
Selective phage infection mediated by epitope expression on F pilus
J. Mol. Biol. 273, 544-551.
150. 1997 Kobayashi, N., Söderlind, E. & Borrebaeck, C.A.K.
Analysis of assembly of synthetic antibody fragments: Expression of functional scFv with predefined specificity
Biotechniques 23, 500-503.
151. 1997 Faber, C., Shan, L. Fan, Z-C., Guddat, L.W., Furebring, C., Ohlin, M., Borrebaeck, C.A.K. & Edmundson, A.B.
Three dimensional structure of a human Fab with high affinity for tetanus toxoid
Immunotechnology 3, 253-270.
152. 1997 Edmundson, A. B. & Borrebaeck, C.A.K.
Progress in programming antibody fragments to crystallize.
Immunotechnology 3, 309-317.
153. 1998 Edmundson, A.B., Goldsteen, B.Z., DeWitt, C.R., Fan, Z., Shan, L., Faber, C., Hanson, B.L. & Borrebaeck, C.A.K.
Designing Fabs and Fvs with propensities to crystallize
The Immunologist 6, 54-60.
154. 1998 Jirholt, P., Ohlin, M., Borrebaeck, C.A.K. & Söderlind, E.
Exploiting sequence space: Shuffling in vivo formed complementarity determining regions into a master framework.
Gene 215, 471-76

155. 1998 Strandh, M., Ohlin, M., Borrebaeck, C.A.K. & Ohlson, S.
New approach to steroid separation based on a low affinity IgM antibody
J. Immunol. Methods 214, 73-79.
156. 1998 Ohlin, M. and Borrebaeck, C. A. K. Insertions and deletions in
hypervariable loops of antibody heavy chains contribute to molecular
diversity.
Mol. Immunol. 35, 233-238
157. 1998 Borrebaeck, C.A.K. Tapping the potential of molecular libraries in
functional genomics.
Immunol. Today 19, 524-27.
158. 1998 Ohlin M., Jirholt P, Thorsteinsdottir H.B., Söderlind E. and Borrebaeck
C.A.K.
Targeting CDR in synthetic antibody design. In: *Antibody Engineering -
New Technology, Application and Commercialisation*. IBC Business
Publ., London. (in press).
159. 1998 Ohlin, M., Jirholt P., Thorsteinsdottir, H.B., Lantto, J., Lindroth, Y. and
Borrebaeck, C.A.K
CDR-shuffling: targeting hyper-variable loops for library construction and
selection. In: *Proceedings of the 10th International Congress of
Immunology*. Monduzzi Editore, Bologna, 1525-1529.
160. 1999 Andersson, T., Furebring, C., Borrebaeck, C.A.K. & Pettersson, S.
Temporal expression of a VH promoter-C μ transgene linked to the IgH
HS1,2 enhancer.
Mol. Immunol. 36, 19-29.
161. 1999 Dueñas M., Rodríguez E., Nilsson N., Everitt E. and Borrebaeck C.A.K.
Synthesis of a eukaryotic virus protein in a prokaryotic viral-cell system:
production of the adenovirus type 2 fiber shaft fragment by a tightly
regulatable T7pol-M13 expression system.
J. Virol. Methods 79, 121-131.
162. 1999 Borrebaeck, C.A.K.
Human monoclonal antibodies: The emperor's new clothes?
Nature Biotech. 17, 621
163. 1999 Ingvarsson, S., Dahlenborg, K., Carlsson, R. & Borrebaeck, C.A.K.
Colligation of CD44 on naive human tonsillar B cells induces a progression
towards a germinal center phenotype

Int. Immunol. 11, 739-744.

164. 1999 Andersson, E., Hendrix, P., Krambovitis, E., Hoogenboom, H. & Borrebaeck, C.A.K.
A tandem repeat of MUC1 core protein induces a weak in vitro immune response in human B cells.
Cancer Immunol. Immunotherapy 47, 249-256.
165. 2000 Ohlin M, Jirholt P, Thorsteinsdottir HB and Borrebaeck CAK
Understanding human immunoglobulin repertoires in vivo and evolving specificities in vitro. In: **The Antibodies**, vol. 6. (Eds. Zanetti M and Capra JD). Harwood Acad. Publ., Amsterdam, pp. 81-104.

166. 2000 Nilsson, N., Malmberg, A.-C., & Borrebaeck, C.A.K.
The phage-infection process: A functional role of the distal linker region of bacteriophage protein 3
J. Virology 74, 4229-4235.
167. 2000 Nilsson, N., Ingvarsson, S. & Borrebaeck, C.A.K.
Immature B cells in bone marrow express Fas/FasL
Scand. J. Immunol. 51, 280-284.
168. 2000 Johansson, B., Ingvarsson, S., Björck, P. & Borrebaeck, C.A.K.
Human interdigitating dendritic cells induce isotype-switching and IL-13 dependent IgM production in CD40 activated naive B cells.
J. Immunol. 164, 1847-1854
169. 2000 Dahlenborg, K., Pound, J., Gordon, J., Borrebaeck, C.A.K. & Carlsson, R.
Identification of signals sustaining mutation of human immunoglobulin V genes.
Immunology 101, 210-217.
170. 2000 Åkesson, A., Ingvarsson, S., Brady, K., Moynagh, P & Borrebaeck, C.A.K.
Rapid polarisation of Th2 cells during induction of antigen-specific IgE antibodies *in vitro*.
Clin. Exp. Allergy 30, 1298-1306.
171. 2000 Borrebaeck, C.A.K.
Antibodies in diagnostics – From immunoassays to protein chips
Immunol. Today 21, 379-382.
172. 2000 Zafiropoulos, A., Kandilogiannaki, M., Dahlenborg, C., Borrebaeck, C.A.K., & Krambovitis, E.
In vitro induction of somatic mutations in human peripheral B lymphocytes
Int. J. Mol. Medicine 6, 475-484.
173. 2000 Gavilondo, J., Larrick, J.W. & Borrebaeck, C.A.K.
Human antibodies for therapy.
The Immunologist 8, 58-65.
174. 2000 Söderlind, E., Strandberg, L., Jirholt, P., Kobayashi, N., Alexeiva, V., Åberg, A.-M., Nilsson, A., Jansson, B., Ohlin, M., Wingren, C., Danielsson, L., Carlsson, R. & Borrebaeck, C.A.K.
Harnessing of proofread diversity into molecular libraries: Random combination of in vivo formed complementarity determining regions into a single antibody framework scaffold.

Nature Biotechnol.18, 852856.

175. 2000 Jirholt, P., Strandberg, L., Jansson, B., Krambovitis, E., Söderlind, E., Borrebaeck, C.A.K., Carlsson, R., Danielsson, L. & Ohlin, M.
A central core structure in an antibody variable domain determines antigen specificity
Protein Eng., in press
176. 2000 Åkesson, A., Ingvarsson, S., Karlsson, F., Coleman, J. & Borrebaeck, C.A.K.
In vitro synthesis of human IgE to allergens *Phlenim pratense* and bezylpenicillin: Optimisation of culture conditions and inter-donor patterns of responsiveness.
Submitted to Int. Arch. Immunol. Allergy
177. 2000 Nilsson, N., Karlsson, F., Raconjac, J. & Borrebaeck, C.A.K.
Dissecting selective infection of E. coli based on specific protein-ligand interactions
Gene, Submitted
178. 2000 Borrebaeck, C., Malmberg Hager, A.-C., Laurell, T., Ekström, S., Nilsson, J. & Marko-Varga
Protein chips based on recombinant antibody fragments. A highly sensitive approach as detected by mass spectrometry
Submitted
- 179.

